Qiming Venture Partners

Qiming Venture Partners is a prominent venture capital firm established in 2006 and headquartered in Shanghai, with additional offices in Beijing, Suzhou, and Hong Kong. The firm specializes in investing in early to growth-stage companies across various sectors, including media and internet, information technology, consumer and retail, healthcare, and clean technology in China. Since its inception, Qiming has built a reputation as a leading investment firm in the region, managing multiple funds with over $1 billion in assets. The firm aims to support promising entrepreneurs and innovative businesses, contributing to the development of China's dynamic economic landscape.

Sam Chen

Associate

Nan Chen

Principal

Anna French

Partner

Jinda Gao

Executive Director

William Hu

Managing Partner

Duane Kuang

Co-Founder & Managing Partner

Grace Lee

Partner

Nisa Leung

Managing Partner

Shuo Mao

vice_president

Mark McDade

Partner

Gary Rieschel

Co-Founder & Managing Partner

Amy Tang

Venture Partner

Shiyu Wang

Partner

Bonnie Wang

Principal

Jing Wu

Partner

Kuantai Yeh

Partner

Janet Yu Ph.D

Partner

Alex Zhou

Partner

Past deals in Series B

Hochuen Medical was founded in 2015 by Dr. Robin Liu, an entrepreneur in IVD medical and microfluidics fields, and Eric Zeng, an expert in the electronics OEM industry. The founding management team has an average of more than 20 years of management experience in manufacturing of microfluidic devices, medical disposables, and consumer electronic products. Dr. Robin Liu, co-founder and president of Hochuen Medical, has more than 20 years of experience in the IVD and microfluidic industry, with experience at Motorola, CombiMatrix, GenMark, Beckman Coulter/Danaher, etc. Dr. Liu brings both experience in R&D and production management in the fields of molecular diagnosis, immunoassays, hematology, urinalysis, etc

Gaugene

Series B in 2022
Gaugene provides hematology testing instruments, reagents, and services for IVD users. Gaugene is a high-tech enterprise co-sponsored by core technology management backbones of well-known domestic IVD companies with rich management experience who master the industry’s top technologies.

Boulder Care

Series B in 2022
Boulder Care, Inc. is a telemedicine-based platform focused on treating opioid addiction through a combination of medication and peer support. Founded in 2017 and located in Portland, Oregon, the company provides comprehensive services that include patient support, medication management, and psychosocial services. By leveraging digital health technology, Boulder Care aims to improve access to effective treatment for individuals struggling with opioid use, enhancing the experience for both patients and their care teams. The organization serves a diverse clientele, including patients, providers, and various health organizations, contributing to the advancement of the behavioral health industry.

Point One

Series B in 2022
Building the next-gen consumer products!

BUD

Series B in 2022
Founded in 2019 by former Snap engineers, Risa Feng and Shawn Lin, Singapore-headquartered BUD is a leading global metaverse UGC platform encouraging users to create and share 3D interactive experiences with its easy-to-use creation tools. Since its global launch in November 2021, BUD skyrocketed to the list of top 10 social apps in more than 38 countries around the world including North America, Southeast Asia and South America. Millions of 3D content has been created and traded on the platform. BUD has become a digital social hub where millions of people come to create, play and hangout.

MeetFuture China

Series B in 2022
MeetFuture China is a technology-driven company that supplies automated transmission systems for the pan-semiconductor industry. It provides automation solutions for leading companies in the semiconductor field since 2016 and provided a highly advantageous overall for industrial upgrading and development with independent and controllable core technologies.

Medilink Therapeutics

Series B in 2022
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.

Deep View Technology

Series B in 2022
Beijing Deep View Technology Co., Ltd. engaged in research on 3D computer vision algorithm. The company is based in Beijing, China.

CureGenetics

Series B in 2022
CureGenetics is a healthcare company focused on the research and development of gene editing technologies and molecular diagnostics. It specializes in creating innovative medicines aimed at providing advanced treatments for cancers and genetic diseases. By developing a gene editing solution and a delivery platform, CureGenetics aims to enhance therapeutic options and improve patient outcomes in the field of genetic medicine.

Korro Bio

Series B in 2022
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.

TUNGEE

Series B in 2021
Guangzhou Tungee Technology Co.,Ltd., a software as a service (SaaS) company, develops intelligent sales cloud platform. It provides leads mining, business opportunity engagement, customer relationship management, and order analysis for enterprises. The company offers Tungee intelligent sales cloud platform , outbound leads, inbound leads, engage, cloud-based call center, intelligent call, and CRM products. It also offers Tungee galaxy, prophecy, and discernment solutions. Guangzhou Tungee Technology Co.,Ltd. was founded in 2016 and is based in Panyu, China.

InfStones

Series B in 2021
Infinity Stones is a Silicon Valley-based company that provides cloud management services and security solutions for blockchains. They are blockchain infrastructure architects with proven track records in the industry. Their team is composed of tech leads, management experts, and financial professionals from tech giants like Google, Oracle, and Intel. Infinity Stones is currently hosting nodes for high net worth individuals, institutional investors, foundations, and universities and research institutions. They make sure every investment with us is secure, and investors can expect returns with consistency. It was founded in 2018 and is headquartered in Palo Alto, California.

DPTechnology

Series B in 2021
DPTechnology, founded in 2018 and based in Beijing, China, specializes in micro-scale industrial design through advanced molecular simulation technology. The company has developed a platform that integrates artificial intelligence with molecular simulation algorithms, aiming to enhance industrial and medical research. By providing users with innovative scientific tools, DPTechnology promotes efficiency and creativity in exploring complex research challenges, thereby establishing a new paradigm in both industrial research and clinical applications.

Wholee

Series B in 2021
Wholee is a member-only zero-markup store.

Cornerstone Robotics

Series B in 2021
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.

Platelet BioGenesis

Series B in 2021
Platelet BioGenesis is a biotechnology company focused on producing donor-independent human platelets from pluripotent stem cells for clinical use. Founded in 2014 and based in Cambridge, Massachusetts, the company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. Platelet BioGenesis distributes these bioreactor-produced platelets to hospitals and blood banks, aiming to provide a reliable source of platelets for patients worldwide. By specializing in the fields of platelets and drug discovery, the company is addressing critical needs in the medical community related to blood supply and treatment options.

Genlight

Series B in 2021
Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.

Okeanos Technology

Series B in 2021
Okeanos Technology specializes in the custom synthesis and production of specialized chemical biological reagents and pharmaceutical intermediates tailored for the life sciences sector. The company's primary offerings include modified nucleotides, unnatural amino acids, heterocycles, and fluorescent and labeling reagents. Okeanos supplies these products to leading pharmaceutical companies, earning a strong reputation for quality and reliability. The firm focuses on providing clients with a diverse range of chemical compounds and biochemical reagents, particularly in the realms of sequencing and synthetic biology.

Qingflow

Series B in 2021
Qingflow is a software-as-a-service platform that enables users to create management systems. Qingflow is located in Minhang District, Shanghai.

Sunyur

Series B in 2021
Sunyur is an e-purchase solution provider.

Ventyx Biosciences

Series B in 2021
Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.

Alamar Biosciences

Series B in 2021
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

moodytiger

Series B in 2021
Moody Tiger is an international activewear brand for children. Moody Tiger was founded in 2018.

Gyenno Science

Series B in 2021
Developer of intelligent medical devices designed for treatment of Parkinson and motor dysfunction. With research and development of intelligent monitoring and assistant devices, the company develops systematic systematic solutions to functional disorders for patients with Parkinson and motor dysfunction, enabling patients to monitor their physical activities and facilitate their movements.

Lingyi Zhihui

Series B in 2021
Zuoshouyisheng's AI ​​doctor platform spans 35 medical specialties and can diagnose more than 6,000 diseases, according to the company’s website. Zuoshouyisheng mainly collaborates with customers through a SaaS business model, providing its AI-empowered healthcare system to hospitals, pharmaceutical companies, employers, and insurers.

Berry Oncology

Series B in 2021
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.

Kingsware

Series B in 2021
Kingsware specializes in developing a robotic process automation system. It is committed to building an enterprise-level safe robot management platform. Its product follows the design concept of safe, easy-to-use, powerful, stable, and efficient, and the system can be deployed and controlled in a large-scale, highly integrated enterprise complex environment.

Health Biotech

Series B in 2021
Beijing Health Biotech Co. Ltd. develops diagnostic and therapeutic products for diagnosis, treatment, and monitoring of Alzheimer's disease. The company offers diagnostic and therapeutic products, such as vitamins detection, Alzheimer's disease detection and treatment, prostate AA detection, ceramides test, therapeutic drug monitoring, and screening of neonatal genetic metabolic diseases for Alzheimer's disease, cardiovascular disease, urinary disease, genetic metabolic disease, therapeutic drug monitoring, metabolite detection, steroid hormone detection, trace element quantitative detection, vitamin family detection, and microbiological identification. It also offers clinical testing and research services. The company was founded in 2016 and is based in Beijing, China.

Hope Medicine

Series B in 2021
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.

Just Medical

Series B in 2021
Just Medical is an artificial orthopedic implant device and system developer.

Tasogare

Series B in 2021
Tasogare Coffee is a Japan-based company specializing in the distribution of high-quality coffee. The company's focus is on providing premium coffee products to customers, ensuring a commitment to quality in its offerings. Through careful sourcing and distribution practices, Tasogare aims to deliver a superior coffee experience.

Zion Pharma

Series B in 2021
Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

Alpha Biopharma

Series B in 2021
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on the research and development of innovative therapeutics. The company is actively developing AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with non-small cell lung cancer who have epidermal growth factor receptor (EGFR) mutations and central nervous system metastases. Alpha Biopharma collaborates with prominent domestic and international pharmaceutical companies to enhance the reliability of its product development. The company employs a strong scientific consulting and management team to optimize its drug development strategies, emphasizing a comprehensive approach that includes research, market positioning, and intellectual property protection. Additionally, Alpha Biopharma partners with top contract research organizations, contract manufacturing organizations, hospitals, and institutes to ensure efficient and organized program implementation, supported by a robust project management system.

Icosavax

Series B in 2021
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. tHEY were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.

imToken

Series B in 2021
imToken Pte. Ltd. is a Singapore-based company that specializes in developing a blockchain-based cryptocurrency wallet and digital asset management tools. Founded in 2016, imToken enables users to manage multi-chain assets and facilitates secure token exchanges within its wallet. The platform features a DApp browser that supports decentralized token-to-token transactions, enhancing the user experience in the blockchain ecosystem. Over the years, imToken has garnered a global user base, becoming one of the largest Ethereum wallets in the world. The company operates as a subsidiary of Hangzhou Rongshi Technology Co., Ltd. and is dedicated to making blockchain technology accessible and user-friendly for a broader audience.

Zhenge Biotech

Series B in 2021
Shanghai ZhenGe Biotechnology Co.,Ltd. researches and develops drugs. It also engages in mammalian cell line development, upstream development, downstream development, and formulation development for various protein therapeutics. In addition, the company provides contract development and manufacturing services; and offers IND and BLA filing services. Further, it provides platform for research and development of antibodies, transient infection, process development, N-Glycosylation, and CAR-T. Shanghai ZhenGe Biotechnology Co.,Ltd. was founded in 2017 and is based in Shanghai, China.

Cool Academy

Series B in 2021
Cool College is a Beijing-based software-as-a-service(SaaS) developer for employee training services.

Hangzhou Weier

Series B in 2021
Weier Technology Co., Ltd, also known as Weier Science, designs and develops robots and software. Its human- machine interaction technology caters e-commerce platforms with customer service, sales and marketing, shopping guide, and customer relations management. Weier Technology Co., Ltd was founded in 2016 and is based in Hangzhou, China. Weier Technology operates in the augmented reality and virtual reality industry. The company is based in Shanghai, China.

Singular Medical

Series B in 2021
Singular Medical is a technology company specializing in R&D and industrialization of cardiac rhythm management (CRM) products. The company builds a complete technical platform and is a supplier of full line of CRM products, which provides a complete range of solutions, from detection to follow-up for large amounts of cardiac patients.

Plum

Series B in 2021
Plum is an e-commerce platform for second-hand fashion products. It works as a one-stop consignment service platform that provides filming, sales, customer service, sale, and a full set of consignment services. Plum was founded on 2015 and is headquartered in Beijing, China.

Morewis

Series B in 2021
Morewis is a Enterprise service provider.

Bouffalo Lab

Series B in 2021
Bouffalo Lab designs and develops semiconductor chips. The company offers integrated Wi-Fi chipsets for low-power and high-performance application development and other products. Its products are used in smart homes, cities, manufacturing, robots, and wearable systems, as well as communication equipment and in-vehicle intelligent systems. The company is based in Shanghai, China.

WeRide

Series B in 2021
Guangzhou WeRide Technology Co., Ltd. develops autonomous driving technology for level 4 AD cars. The company also develops own AD hardware solution to fit on cars for surround sensor coverage and full spectrum. The company was founded in 2017 and is headquartered in Guangzhou, China.

Vistel

Series B in 2021
Vistel is a technology-based firm that focuses on the use of artificial intelligence (AI) in the medical field. Vistel was founded in 2016 by Sun Yuhui and Ding Dayong.

Kira Pharma

Series B in 2021
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

Elevation Oncology

Series B in 2020
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, the company focuses on developing targeted therapies that inhibit specific genetic alterations associated with cancer progression. Its lead candidate, seribantumab, is designed to address tumor growth driven by NRG1 fusions and is currently undergoing clinical evaluation in the Phase 2 CRESTONE study, which includes patients with various tumor types exhibiting this genomic alteration. Through its innovative approach, Elevation Oncology aims to enhance treatment options for individuals with solid tumors linked to specific genetic drivers.

Talaris Therapeutics

Series B in 2020
Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

Shukun Technology

Series B in 2020
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.

TUNGEE

Series B in 2020
Guangzhou Tungee Technology Co.,Ltd., a software as a service (SaaS) company, develops intelligent sales cloud platform. It provides leads mining, business opportunity engagement, customer relationship management, and order analysis for enterprises. The company offers Tungee intelligent sales cloud platform , outbound leads, inbound leads, engage, cloud-based call center, intelligent call, and CRM products. It also offers Tungee galaxy, prophecy, and discernment solutions. Guangzhou Tungee Technology Co.,Ltd. was founded in 2016 and is based in Panyu, China.

Shukun Technology

Series B in 2020
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.

Luc Therapeutics

Series B in 2020
Luc Therapeutics, founded in 2010 and based in Cambridge, Massachusetts, was a precision neuroscience company focused on developing novel allosteric modulators for ion channels aimed at improving neuronal firing regularity. The company specialized in creating subunit-selective NMDA receptor modulators, including NR2B negative allosteric modulators for depression and NR2B positive allosteric modulators to enhance cognitive function in schizophrenia. Additionally, it explored NR2A negative allosteric modulators to address disease progression and symptoms in Rett syndrome and other autism spectrum disorders. Luc Therapeutics was known for its innovative approach to restoring cognitive and motor functions in patients with serious neurological conditions by leveraging target specificity, patient selection, and drug optimization. In October 2017, Luc Therapeutics changed its name to Cadent Therapeutics.

Kira Pharma

Series B in 2020
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. The company specializes in the development of complement-targeted therapies and antibody drugs aimed at treating immune-mediated diseases. Kira Pharmaceuticals focuses on research, development, and production of innovative antibody therapies that provide improved treatment options for patients with complement-mediated conditions. By targeting immune modulation, the company strives to offer transformative solutions to enhance patient care and outcomes in various disease areas.

Bouffalo Lab

Series B in 2020
Bouffalo Lab designs and develops semiconductor chips. The company offers integrated Wi-Fi chipsets for low-power and high-performance application development and other products. Its products are used in smart homes, cities, manufacturing, robots, and wearable systems, as well as communication equipment and in-vehicle intelligent systems. The company is based in Shanghai, China.

Nice Tuan

Series B in 2020
Nice Tuan is an e-commerce platform that specializes in providing daily groceries and a variety of household products. The company collaborates with local residential communities to source items from nearby warehouses and producers, ensuring a wide selection of fresh produce and essential goods for residents. By focusing on creating a convenient and efficient community e-commerce ecosystem, Nice Tuan aims to enhance the shopping experience for local consumers while supporting local suppliers.

Vongi

Series B in 2019
Vongi is a clinical medicine-based chronic disease patient management platform.

Chaodian Culture

Series B in 2019
Chaodian Culture

Newsoara

Series B in 2019
Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Genius

Series B in 2019
Genius was founded in February 2017 to focus on the field of K12 artificial intelligence education.

Nice Tuan

Series B in 2019
Nice Tuan is an e-commerce platform that specializes in providing daily groceries and a variety of household products. The company collaborates with local residential communities to source items from nearby warehouses and producers, ensuring a wide selection of fresh produce and essential goods for residents. By focusing on creating a convenient and efficient community e-commerce ecosystem, Nice Tuan aims to enhance the shopping experience for local consumers while supporting local suppliers.

61Draw.com

Series B in 2019
Art Class is a children's classroom teaching service provider. The teaching and research team draws on the cutting-edge education concept of the front and the back at home and abroad, and conducts field research in 32 first-tier cities, combined with the test results of hundreds of real-life experiences of the family, to develop a child-friendly nature. Course outline and teaching methods. For the families of children aged 5~12 years old, we provide one-on-one after-school tutoring services for the four major artists in the country. Currently, Lala is mainly using a third-party platform for online instruction, choosing a fixed class and a fixed teacher, because continuity and stability are very important for students to learn skills and aesthetics. However, based on the actual needs of art teaching, painting will also develop its own live teaching system.

dMed

Series B in 2019
dMed Company Limited, also known as, dMed Biopharmaceutical Co., Ltd. operates as clinical contract research organization providing services for development of medicines and medical devices. The company offer services, including consulting, clinical operations, biostatistics & programming, data management, pharmacovigilance, clinical science & medical affairs, quality assurance, and regulatory affairs & Strategy. It serves biopharmaceutical and medical device companies. dMed Company Limited was founded in 2016 and is based in Shanghai, China.

TigerGraph

Series B in 2019
TigerGraph is a provider of a graph database platform for enterprise applications. It fulfills the true promise and benefits of the graph platform by supporting real-time deep link analytics for enterprises with complex and colossal amounts of data. TigerGraph’s proven technology is used by customers including Alipay, VISA, SoftBank, State Grid Corporation of China, Wish and Elementum. The company supports applications such as IoT, AI, and machine learning to make sense of ever-changing big data. It also provides personalized recommendations, fraud prevention, supply-chain logistics, company knowledge graph, and other features. Founded by Yu Xu, Ph.D. in 2012, TigerGraph is funded by Qiming VC, Baidu, Ant Financial, AME Cloud, Morado Ventures, Zod Nazem, Danhua Capital, and DCVC. TigerGraph is based in Redwood City, CA.

Plum

Series B in 2019
Plum is an e-commerce platform for second-hand fashion products. It works as a one-stop consignment service platform that provides filming, sales, customer service, sale, and a full set of consignment services. Plum was founded on 2015 and is headquartered in Beijing, China.

Insilico Medicine

Series B in 2019
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.

Insilico Medicine

Series B in 2019
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.

TUNGEE

Series B in 2019
Guangzhou Tungee Technology Co.,Ltd., a software as a service (SaaS) company, develops intelligent sales cloud platform. It provides leads mining, business opportunity engagement, customer relationship management, and order analysis for enterprises. The company offers Tungee intelligent sales cloud platform , outbound leads, inbound leads, engage, cloud-based call center, intelligent call, and CRM products. It also offers Tungee galaxy, prophecy, and discernment solutions. Guangzhou Tungee Technology Co.,Ltd. was founded in 2016 and is based in Panyu, China.

MyHealthTeams

Series B in 2019
MyHealthTeams is a San Francisco-based company building deeply engaging social networks for people living chronic conditions. MyHealthTeams is leading the way in patient engagement, making it easy for consumers to find and connect with others who understand what they face daily because they have been in their shoes. Eric Peacock & Mary Ray co-founded MyHealthTeams in 2012. As of 2019, MyHealthTeams has built and operates over 30 social networks to serve 90% of the addressable chronic condition population in 13 countries.

Chuman

Series B in 2019
Chuman is a UGC Pan-Secondary Creation Community, providing creative platforms and studios for comic creators, and providing IP incubation and resource docking services. Users can quickly generate a lot of content through third-party or official materials, and can make friends, transactions and other activities within the community through the creation, while the APP also supports the dialogue novel reading function.

Dingdong Maicai

Series B in 2019
Dingdong Maicai is a rapidly growing online retail platform based in Shanghai, China, specializing in the sale of fresh produce and daily necessities. Founded in 2014, the company leverages a big data-driven approach to optimize its operations and improve customer experience. By utilizing self-developed data models and historical sales data, Dingdong Maicai predicts future orders, which helps reduce waste and ensure product availability. The platform offers a wide range of products, including fresh vegetables, seafood, meat, fruits, and organic items. Customers can conveniently shop through the Dingdong Fresh app and mini-programs, which facilitate direct delivery to households. The company generates revenue primarily through the sale of these fresh groceries and membership services, establishing itself as a key player in the community-based e-commerce sector in China.

61Draw.com

Series B in 2019
Art Class is a children's classroom teaching service provider. The teaching and research team draws on the cutting-edge education concept of the front and the back at home and abroad, and conducts field research in 32 first-tier cities, combined with the test results of hundreds of real-life experiences of the family, to develop a child-friendly nature. Course outline and teaching methods. For the families of children aged 5~12 years old, we provide one-on-one after-school tutoring services for the four major artists in the country. Currently, Lala is mainly using a third-party platform for online instruction, choosing a fixed class and a fixed teacher, because continuity and stability are very important for students to learn skills and aesthetics. However, based on the actual needs of art teaching, painting will also develop its own live teaching system.

Pratilipi

Series B in 2019
Pratilipi is a platform which brings readers, writers and their stories together. From the next door neighbour reading stories in the afternoon, to the funny college kid downstairs, millions of people around you are using Pratilipi to discover, express and share their stories in the language they love.

SinoUnited Health

Series B in 2019
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.

LetsGetChecked

Series B in 2019
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

Coffee Box

Series B in 2019
Coffee Box is a coffee chain brand that provides express delivery services.

INXX

Series B in 2019
Hangzhou INXX Fashion Co,. Ltd. retails apparels and accessories through the Internet. The company is based in Hangzhou, China.

Anxin Doctor

Series B in 2019
Anxin Doctor is a mobile maternal and pediatric health platform that connects patients with obstetrics, gynecology doctors and pediatrics doctors.

Abbisko Therapeutics

Series B in 2019
Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Emergen

Series B in 2019
Zhejiang Zhichang Group is a cluster of robots and intelligent manufacturing enterprises founded by Dr. Gan Middle School, the first batch of national “Thousand Talents Program” experts. It has two independent core technologies: distributed intelligent robot controller and HCPS intelligent intellectual network. Three single-arm robots and smart factory eco-networks are three high-end intelligent manufacturing business areas. Committed to the development of robotic products with independent intellectual property rights, breaking the monopoly of foreign brands in the field of key components of robots, and truly realizing the national dream of "intellectual creation".

RedDoorz

Series B in 2019
RedDoorz is an online platform that facilitates budget accommodations across Southeast Asia, catering to both travelers and hoteliers. Founded in 2015 and headquartered in Jakarta, Indonesia, the company operates a network of branded budget hotels, providing its partners with tools for distribution, marketing, technology, customer experience, and pricing. This end-to-end platform allows guest house owners and hotel operators to enhance their visibility, reach a broader audience, and streamline their operations. RedDoorz has expanded significantly, employing over 1,000 individuals across five countries and attracting investment from notable backers. The platform focuses on two-star and three-star budget hotels, enabling travelers to discover affordable lodging options in key business and tourist destinations.

Xiaobu

Series B in 2019
Sharp Network is an operator of news App based on recommendation engine focusing on south-east Asia market. The App was first launched in Vietnam, whose people have on average the highest education level and the best consumption .
NASN Automotive Electronics is committed to providing advanced and complete chassis electronic control products, ADAS and autonomous driving related core technologies for the Chinese automotive market. The main products include NBooster intelligent brake system, brushless electric steering EPS controller and wire control system. It is a scientific and technological innovation enterprise integrating R&D, production and sales.
Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

Antengene Corporation

Series B in 2019
Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in developing innovative oncology therapies aimed at treating various types of cancer. Its product pipeline includes ATG-008, an orally available mTOR kinase inhibitor for advanced solid tumors and hematological malignancies, and ATG-010, a compound targeting the XPO1 protein for hematologic cancers like multiple myeloma. Additionally, Antengene is advancing several other candidates in different stages of development, including ATG-016, ATG-527, and ATG-019, which target various oncological conditions. The company is committed to addressing unmet medical needs in Asia through its research and development efforts focused on anti-tumor and anti-cancer therapies.

ABC Fintech

Series B in 2018
Beijing ABC Fintech Co., Ltd., founded in 2016 and headquartered in Beijing, China, specializes in providing artificial intelligence-driven cloud services tailored for the financial sector. The company's key products, Modeling.ai and Eversight.ai, are designed to enhance the efficiency of equity research and investment decision-making processes within financial institutions, while also offering predictive analytics for future trends. ABC Fintech has successfully raised a total of $60 million from various investors, including Qiming Venture Partners and Source Code Capital, indicating strong support for its innovative approach in the fintech landscape.

WorkTrans

Series B in 2018
Shanghai WorkTrans Information Technology Co., Ltd. develops human resource (HR) management software. The company's software solution tracks and analyzes enterprise resource planning (ERP) data and employee performance to estimate the number of work hours and employee skills required in the next phase. It also develops an integrated personnel management platform that integrates payroll, rosters, recruitment, and training solutions. The company was founded in 2015 and is based in Shanghai, China.

Luc Therapeutics

Series B in 2018
Luc Therapeutics, founded in 2010 and based in Cambridge, Massachusetts, was a precision neuroscience company focused on developing novel allosteric modulators for ion channels aimed at improving neuronal firing regularity. The company specialized in creating subunit-selective NMDA receptor modulators, including NR2B negative allosteric modulators for depression and NR2B positive allosteric modulators to enhance cognitive function in schizophrenia. Additionally, it explored NR2A negative allosteric modulators to address disease progression and symptoms in Rett syndrome and other autism spectrum disorders. Luc Therapeutics was known for its innovative approach to restoring cognitive and motor functions in patients with serious neurological conditions by leveraging target specificity, patient selection, and drug optimization. In October 2017, Luc Therapeutics changed its name to Cadent Therapeutics.

Haoyiku

Series B in 2018
Haoyiku, founded in 2017 by Qiangqiang Wu and based in Hangzhou, China, operates as a community-based e-commerce platform specializing in apparel. The company is part of the Webuy/Jingling Group, which includes various brands and focuses on social e-commerce. Haoyiku allows merchants to share links to items for sale through WeChat, enabling customers to make direct purchases within the app. This business model leverages social media to enhance the shopping experience and facilitate connections between merchants and consumers.

Shiyunji

Series B in 2018
Shiyunji doing business as Chomp Cloud, operates a food court that uses mobile and cloud technology to streamline both sales and purchasing. The company has also developed a proprietary software-as a-service (SaaS) which collects orders and distributes them to the correct food vendor, helping them streamline transactions. Additionally, It also provides hardware, software solutions, store operation, brand promotion, and infrastructural services. The company was founded in 2016 and is based in Nanjing, China.

Eigen

Series B in 2018
Eigen is applying the latest AI technologies to variety of business domains, making AI the center of thegravity in industrial evolutions.

Haoyiku

Series B in 2018
Haoyiku, founded in 2017 by Qiangqiang Wu and based in Hangzhou, China, operates as a community-based e-commerce platform specializing in apparel. The company is part of the Webuy/Jingling Group, which includes various brands and focuses on social e-commerce. Haoyiku allows merchants to share links to items for sale through WeChat, enabling customers to make direct purchases within the app. This business model leverages social media to enhance the shopping experience and facilitate connections between merchants and consumers.

DST Car

Series B in 2018
DiShangTie Car Rental (Shenzhen) Co., Ltd. is a Shenzhen-based company that specializes in the rental and maintenance of commercial electric vehicles (EVs) for both passenger and cargo transportation in China. Founded in 2015, the company also manufactures electric car charging stations, catering to the growing demand for sustainable transportation solutions. By focusing on the transportation and logistics industry, DiShangTie aims to facilitate the adoption of new energy vehicles in the region.

DST Car

Series B in 2018
DiShangTie Car Rental (Shenzhen) Co., Ltd. is a Shenzhen-based company that specializes in the rental and maintenance of commercial electric vehicles (EVs) for both passenger and cargo transportation in China. Founded in 2015, the company also manufactures electric car charging stations, catering to the growing demand for sustainable transportation solutions. By focusing on the transportation and logistics industry, DiShangTie aims to facilitate the adoption of new energy vehicles in the region.

CardiaLen

Series B in 2018
Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.